Robert F. Apple, Chief Operating Officer
InKine Pharmaceutical Company, Inc.

Donald C. Weinberger
Wolfe Axelrod Weinberger Assoc. LLC
212-370-4500, 212-370-4505 fax
[email protected]



BLUE BELL, PA November 25, 2003 -- InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced the filing of a provisional United States patent application for a new generation of purgative products.   The inventors include Stephen Skiendzielewski, Vice President of Manufacturing and Martin Rose, M.D., J.D., Executive Vice President of Research and Development, both of InKine.

The invention covers several highly soluble colonic purgative formulations in solid dosage forms that can be used to soften stool, promote laxation and/or induce complete purgation.   If a patent issues, the new product will be protected for a significant period beyond the 2013 patent expiration of our current franchise product, Visicol.

Clinical batches of this new product have been manufactured and formulated to yield smaller tablets that may be easier to ingest.   Additionally, the new product does not contain any microcrystalline cellulose, or MCC, which is a common inert, but highly insoluble excipient.    Finally, the Company plans to conduct clinical studies and apply for FDA approval of this new product using alternative dosing regimens that utilize fewer tablets and allow for single-day administration.

"We are excited about this new patent filing which will continue to build upon the existing competitive advantages of our franchise product, Visicol.   We are committed to improving our products to make them the most acceptable to both physicians and patients and to help maintain a sustainable competitive advantage in our markets," said Leonard S. Jacob, M.D., Ph.D., Chairman and CEO of InKine.   "An MCC-free product is a great example of our team's efforts.   We believe that FDA approval of this new product, with a reduced tablet dosing regimen and single-day administration, would increase the acceptance of our product and quickly gain market share.   This highly soluble, new generation product should provide physicians additional flexibility to better meet their patients' needs and schedules," added Dr. Jacob.

About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded specialty pharmaceutical company focused on developing and commercializing pharmaceutical products for the diagnosis and treatment of gastrointestinal disorders. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's franchise product, Visicol ® is the only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IB-Stat ® , is an oral hyoscyamine spray for the treatment of a variety of indications.   Additionally, the Company is developing Colirest(TM), which is in clinical trials for the treatment of Crohn's disease. For further information, please visit InKine on its web site http://www.inkine.com .

In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.